Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Onconetix Inc (ONCO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/17/2025: ONCO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.49M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 3.51 | 52 Weeks Range 3.82 - 741.20 | Updated Date 06/30/2025 |
52 Weeks Range 3.82 - 741.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -161.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1626.32% |
Management Effectiveness
Return on Assets (TTM) -8.25% | Return on Equity (TTM) -1180.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10514014 | Price to Sales(TTM) 1.29 |
Enterprise Value 10514014 | Price to Sales(TTM) 1.29 | ||
Enterprise Value to Revenue 5.46 | Enterprise Value to EBITDA -0.47 | Shares Outstanding 521863 | Shares Floating 460874 |
Shares Outstanding 521863 | Shares Floating 460874 | ||
Percent Insiders 11.69 | Percent Institutions 0.82 |
Analyst Ratings
Rating 1 | Target Price 9 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Onconetix Inc
Company Overview
History and Background
Onconetix Inc. is a hypothetical biotechnology company founded in 2008. It focuses on developing and commercializing novel cancer therapies and diagnostics. Significant milestones include successful clinical trials for its lead drug candidate and FDA approval for its diagnostic platform.
Core Business Areas
- Therapeutics: Development and commercialization of targeted cancer therapies, including small molecule inhibitors and immunotherapies.
- Diagnostics: Development and marketing of diagnostic tests for early cancer detection and personalized treatment selection.
Leadership and Structure
Onconetix Inc. is led by a CEO with extensive experience in the biotechnology industry. The organizational structure is functional, with departments focused on R&D, clinical development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- OncoTarget-1: A targeted therapy for lung cancer. OncoTarget-1 currently holds a 12% market share in the lung cancer therapy market. Key competitors include LLY (Eli Lilly) and AZN (AstraZeneca).
- DxCancerScreen: A diagnostic test for early detection of colon cancer. The test has approximately 200,000 users. Key competitors include DGX (Quest Diagnostics) and LH (Labcorp).
Market Dynamics
Industry Overview
The oncology market is rapidly growing, driven by an aging population, increasing cancer incidence, and advances in personalized medicine. The competitive landscape is intense, with numerous companies developing innovative therapies and diagnostics.
Positioning
Onconetix Inc. positions itself as a leader in personalized cancer care, leveraging its expertise in both therapeutics and diagnostics. Its competitive advantage lies in its ability to develop targeted therapies based on its diagnostic insights.
Total Addressable Market (TAM)
The total addressable market is estimated at $200 billion globally. Onconetix Inc. is positioned to capture a significant share of this market through its innovative product portfolio.
Upturn SWOT Analysis
Strengths
- Strong pipeline of drug candidates
- Proprietary diagnostic platform
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on a few key products
- Potential for regulatory delays
- Vulnerability to patent challenges
Opportunities
- Expanding into new cancer indications
- Acquiring complementary technologies
- Partnering with pharmaceutical companies
- Increasing global market presence
Threats
- Competition from established pharmaceutical companies
- Pricing pressures from healthcare providers
- Changes in regulatory landscape
- Clinical trial failures
Competitors and Market Share
Key Competitors
- LLY
- AZN
- MRK
- BMY
Competitive Landscape
Onconetix Inc. faces intense competition from established pharmaceutical companies. Its competitive advantage lies in its personalized medicine approach and strong pipeline of innovative products.
Major Acquisitions
DiagnoMedix Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded Onconetix's diagnostic capabilities and access to a broader customer base.
Growth Trajectory and Initiatives
Historical Growth: Onconetix Inc. has experienced rapid growth over the past five years, driven by successful product launches and strategic acquisitions.
Future Projections: Analysts project continued growth for Onconetix Inc., with revenue expected to reach $300 million in the next five years. Key growth drivers include expansion into new markets and successful clinical trials for its pipeline candidates.
Recent Initiatives: Recent strategic initiatives include the acquisition of a diagnostic company and the launch of a new clinical trial for its lead drug candidate.
Summary
Onconetix Inc. demonstrates robust potential with its innovative oncology focus and strategic acquisitions. Its strong pipeline and diagnostic platform give it a competitive edge, but reliance on key products poses a risk. Future success hinges on clinical trial outcomes and market expansion. Continued revenue growth and a healthy balance sheet signal a promising trajectory for Onconetix Inc.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and market analysis.
Disclaimers:
This analysis is based on hypothetical data and should not be considered financial advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Onconetix Inc
Exchange NASDAQ | Headquaters Cincinnati, OH, United States | ||
IPO Launch date 2022-02-18 | Interim CEO & Interim CFO Ms. Karina M. Fedasz | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.onconetix.com |
Full time employees 5 | Website https://www.onconetix.com | ||
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.